AAV Vectored Immunoprophylaxis for Prevention of Respiratory Infectious Diseases

This project aims to provide an alternative therapeutic for the prevention and treatment of the virus responsible for COVID-19, SARS-CoV-2, as well as respiratory syncytial virus and influenza. Using a single viral vector platform, we will deliver antibodies from human survivors of these diseases to provide sustained levels of protection against the virus for all patients, including the elderly and immunocompromised. This project will help Avamab Pharma Inc. brings its first treatment to clinical trials, with the ultimate goal of providing patient populations with a universal therapeutic treatment to combat a variety of respiratory pathogens of public health concern.

Amira Rghei
Faculty Supervisor: 
Sarah Wootton
Partner University: